Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RXSD Rexall Sundown -- Ignore unavailable to you. Want to Upgrade?

To: Gator who wrote (273)	6/15/1999 9:29:00 PM
From: Adelantado	Read Replies (1) \| Respond to of 327

Earnings are up, but not up enough for first call's taste. Seems to me that first call didn't factor into its forcast the incertainty of Celulite's market acceptance. So, the market not liking RXSD's failure to meet first call's wrong estimate bailed out. I'll wait a few more days till price drops to about 8, then come in with wads and wads of cash that will multiply by next October. Joe.

To: Gator who wrote (273)	6/15/1999 10:21:00 PM
From: mike cobble	Respond to of 327

Oh Gator, who's to say where this stock price belongs. Fair market value based on the PE and reflected earnings growth this q place it at $11.25 right where we are. Surprise, surprise. There is no doubt that rxsd is the market leader in this competitive industry, what cycles down will cycle up. Guess we'll see what the next couple days have in store. Liked the downgrades today. m